Revolutionizing Treatment in the Battle Against Blood Cancer Post author:andrewkaretas Post published:April 28, 2021 Post category:Perspectives Continue ReadingRevolutionizing Treatment in the Battle Against Blood Cancer
PD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:April 18, 2021 Post category:PLATFORM/Scientific Publications Continue ReadingPD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs
Preclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma Post author:andrewkaretas Post published:December 22, 2020 Post category:BCMA/Scientific Publications Continue ReadingPreclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma
Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML Post author:andrewkaretas Post published:December 18, 2020 Post category:CD70/Scientific Publications Continue ReadingInvestigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML
First-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study) Post author:andrewkaretas Post published:December 9, 2020 Post category:BCMA/Scientific Publications Continue ReadingFirst-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery Post author:andrewkaretas Post published:October 18, 2020 Post category:FLT3/Scientific Publications Continue ReadingAllogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
American Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:June 18, 2020 Post category:PLATFORM/Scientific Publications Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs
American Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer Post author:andrewkaretas Post published:June 18, 2020 Post category:DLL3/Scientific Publications Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer
Positive Progress in AlloCAR T:The Revolution in Cell Therapy is on the Horizon Post author:andrewkaretas Post published:May 29, 2020 Post category:Perspectives Continue ReadingPositive Progress in AlloCAR T:The Revolution in Cell Therapy is on the Horizon
American Society of Gene and Cell Therapy (ASGCT) May 2020 – TurboCAR™ T Cells: CAR T Cells with Constitutive, Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:May 18, 2020 Post category:PLATFORM/Scientific Publications Continue ReadingAmerican Society of Gene and Cell Therapy (ASGCT) May 2020 – TurboCAR™ T Cells: CAR T Cells with Constitutive, Programmable Cytokine Signaling Outputs
